Literature DB >> 25304718

Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy.

T Jonathan Yang1, Jung Hun Oh2, Aditya Apte2, Christina H Son1, Joseph O Deasy2, Karyn A Goodman3.   

Abstract

BACKGROUND AND
PURPOSE: To identify clinical and dosimetric factors associated with hematologic toxicity (HT) during chemoradiotherapy for rectal cancer.
MATERIALS AND METHODS: We analyzed 120 rectal cancer patients treated with neoadjuvant pelvic radiotherapy (PRT) with concurrent 5-fluorouracil-based chemotherapy. The coxal (ilium, ischium, and pubis) bone marrow (BM), sacral BM, and femoral BM were contoured and dose-volume parameters were extracted. Associations between cell count trend and clinical predictors were tested using repeated-measures analysis of variance (ANOVA) test. Associations between clinical variables, Vx (percentage volume receiving x Gy), and cell count ratio at nadir were tested using linear regression models.
RESULTS: Nadirs for white blood cell count (WBC), absolute neutrophil count (ANC), and platelets (PLT) occurred in the second week of PRT and the fifth week for hemoglobin and absolute lymphocyte count (ALC). Using cell count ratio, patients treated with 3DCRT had a lower WBC ratio trend during PRT compared to patients treated with IMRT (p=0.04), and patients ⩾59 years of age had a lower hemoglobin ratio trend during PRT (p=0.02). Using absolute cell count, patients treated with 3DCRT had lower ANC cell count trend (p=0.03), and women had lower hemoglobin cell count trend compared to men (p=0.03). On univariate analysis, use of 3DCRT was associated with a lower WBC ratio at nadir (p=0.02). On multiple regression analysis using dosimetric variables, coxal BM V45 (p=0.03) and sacral BM V45 (p=0.03) were associated with a lower WBC and ANC ratio at nadir, respectively.
CONCLUSIONS: HT trends during PRT revealed distinct patterns: WBC, ANC, and PLT cell counts reach nadirs early and recover, while hemoglobin and ALC decline steadily. Patients who were treated with 3DCRT and older patients experienced lower cell count ratio trend during PRT. Dosimetric constraints using coxal BM V45 and sacral BM V45 can be considered.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Acute radiation toxicity; Clinical predictors; Dose constraint; Rectal cancer

Mesh:

Substances:

Year:  2014        PMID: 25304718      PMCID: PMC4822505          DOI: 10.1016/j.radonc.2014.09.002

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  25 in total

1.  Effect of fractionated regional external beam radiotherapy on peripheral blood cell count.

Authors:  B Zachariah; S S Jacob; C Gwede; A Cantor; J Patil; L Casey; A B Zachariah
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-06-01       Impact factor: 7.038

2.  CERR: a computational environment for radiotherapy research.

Authors:  Joseph O Deasy; Angel I Blanco; Vanessa H Clark
Journal:  Med Phys       Date:  2003-05       Impact factor: 4.071

3.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

4.  Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Rectal Cancer Study Group.

Authors: 
Journal:  Cancer       Date:  1990-07-01       Impact factor: 6.860

Review 5.  Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy.

Authors:  P Mauch; L Constine; J Greenberger; W Knospe; J Sullivan; J L Liesveld; H J Deeg
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

6.  A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma.

Authors:  R J Myerson; V Valentini; E H Birnbaum; N Cellini; C Coco; J W Fleshman; M A Gambacorta; D Genovesi; I J Kodner; J Picus; G A Ratkin; T E Read
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-08-01       Impact factor: 7.038

7.  The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group.

Authors:  B Cedermark; H Johansson; L E Rutqvist; N Wilking
Journal:  Cancer       Date:  1995-05-01       Impact factor: 6.860

8.  Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

Authors:  W Scheithauer; J McKendrick; S Begbie; M Borner; W I Burns; H A Burris; J Cassidy; D Jodrell; P Koralewski; E L Levine; N Marschner; J Maroun; P Garcia-Alfonso; J Tujakowski; G Van Hazel; A Wong; J Zaluski; C Twelves
Journal:  Ann Oncol       Date:  2003-12       Impact factor: 32.976

9.  Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.

Authors:  M J O'Connell; J A Martenson; H S Wieand; J E Krook; J S Macdonald; D G Haller; R J Mayer; L L Gunderson; T A Rich
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

10.  Preoperative infusional chemoradiation and surgery with or without an electron beam intraoperative boost for advanced primary rectal cancer.

Authors:  G D Weinstein; T A Rich; C R Shumate; J M Skibber; K R Cleary; J A Ajani; D M Ota
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-04-30       Impact factor: 7.038

View more
  15 in total

1.  Bone marrow tolerance during postoperative chemotherapy in colorectal carcinomas.

Authors:  Neil B Newman; Rebecca A Moss; Nell Maloney-Patel; Kristen Donohue; Teresa V Brown; Michael J Nissenblatt; Shou-En Lu; Salma K Jabbour
Journal:  J Gastrointest Oncol       Date:  2017-06

2.  Dosimetric predictors of acute haematological toxicity in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy.

Authors:  Jie Lee; Jhen-Bin Lin; Fang-Ju Sun; Kuo-Wei Lu; Chou-Hsien Lee; Yu-Jen Chen; Wen-Chien Huang; Hung-Chang Liu; Meng-Hao Wu
Journal:  Br J Radiol       Date:  2016-08-24       Impact factor: 3.039

3.  Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation.

Authors:  Pierfrancesco Franco; Christian Fiandra; Francesca Arcadipane; Elisabetta Trino; Francesca Romana Giglioli; Riccardo Ragona; Umberto Ricardi
Journal:  BMC Cancer       Date:  2017-11-02       Impact factor: 4.430

4.  Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer.

Authors:  Neil B Newman; Joshua L Anderson; Alexander D Sherry; Evan C Osmundson
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 2.895

5.  The Impact of Novel Radiation Treatment Techniques on Toxicity and Clinical Outcomes In Rectal Cancer.

Authors:  Lara Hathout; Terence M Williams; Salma K Jabbour
Journal:  Curr Colorectal Cancer Rep       Date:  2017-03-10

6.  Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?

Authors:  Juefeng Wan; Kaitai Liu; Kaixuan Li; Guichao Li; Zhen Zhang
Journal:  Radiat Oncol       Date:  2015-08-04       Impact factor: 3.481

7.  Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer.

Authors:  Maxwell Robinson; Ahmed Sabbagh; Rebecca Muirhead; Lisa Durrant; Frank Van den Heuvel; Maria Hawkins
Journal:  Radiother Oncol       Date:  2015-09-22       Impact factor: 6.280

8.  Temporal changes in immune cell composition and cytokines in response to chemoradiation in rectal cancer.

Authors:  Yong Joon Lee; Sat Byol Lee; Suk Kyung Beak; Yoon Dae Han; Min Soo Cho; Hyuk Hur; Kang Young Lee; Nam Kyu Kim; Byung Soh Min
Journal:  Sci Rep       Date:  2018-05-15       Impact factor: 4.379

9.  Dosimetric analysis and comparison of reduced longitudinal cranial margins of VMAT-IMRT of rectal cancer.

Authors:  Hendrik Dapper; Markus Oechsner; Stefan Münch; Kai Borm; Jan Peeken; Michael Mayinger; Stephanie E Combs; Daniel Habermehl
Journal:  Radiat Oncol       Date:  2018-09-06       Impact factor: 3.481

10.  Leukotoxicity after moderately Hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate Cancer: a secondary analysis from a randomized study.

Authors:  Giuseppe Sanguineti; Diana Giannarelli; Maria Grazia Petrongari; Stefano Arcangeli; Angelo Sangiovanni; Biancamaria Saracino; Alessia Farneti; Adriana Faiella; Mario Conte; Giorgio Arcangeli
Journal:  Radiat Oncol       Date:  2019-01-30       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.